1
|
Wakamoto S, Fujihara M, Akino M, Katsumata M, Naito Y, Hayashi Y, Homma C, Kino S, Ikeda H, Takamoto S. Evaluation of ADAM-rWBC for counting residual leucocytes in leucocyte-reduced whole blood and apheresis platelet concentrates. Transfus Med 2016; 26:231-5. [PMID: 27117675 DOI: 10.1111/tme.12306] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2015] [Revised: 03/30/2016] [Accepted: 03/30/2016] [Indexed: 11/26/2022]
Affiliation(s)
- S Wakamoto
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| | - M Fujihara
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| | - M Akino
- Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan
| | - M Katsumata
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| | - Y Naito
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| | - Y Hayashi
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| | - C Homma
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| | - S Kino
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| | - H Ikeda
- Hokkaido Red Cross Blood Center, Sapporo, Japan
| | - S Takamoto
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| |
Collapse
|
2
|
Ryu SW, Suh IB. [New leukocyte counting method of cerebrospinal fluid: using transparent ruler tape]. Korean J Lab Med 2007; 27:394-9. [PMID: 18160828 DOI: 10.3343/kjlm.2007.27.6.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND To enumerate leukocyte count in cerebrospinal fluid (CSF) is important for diagnosing bacterial meningitis. Using automated hematology analyzer for enumeration of leukocyte in CSF is below the sensitivity, so microscopic hemocytometric method is standard method. But this requires sufficient practical experience and has limitation of accuracy and stability. So we developed new manual method and evaluated it. METHODS We designed new method using transparent ruler tape. We performed correlation, accuracy and precision test by counting leukocyte in diluted EDTA blood with three methods: new method, Neubauer and Nageotte hemocytometry. Twenty two CSF were used for stability test, which determines leukocyte count according to time (within one hour and after 2, 4 and 12 hr), by new method and Neubauer hemocytometry at room temperature. RESULTS There was no clinical significant difference between three methods in correlation test, whereas Neubauer and Nageotte hemocytometry showed a bias to underestimation relative to the results obtained with new method in case with low leukocyte count. The new method showed the lowest CV and most accurate result. In stability test, leukocyte counts decreased being 44.4%, 72.1% of initial values after 2 hr, 14.8%, 31.1%, after 4 hr and 4.2%, 8.7%, after 12 hr, by Nageotte hemocytometry and new method, respectively. CONCLUSIONS The new method we devised is simple, easy and applicable to use in a laboratory and offers advantages of improved precision and stability. It may be sufficient for replacing standard methods for leukocyte counting in CSF.
Collapse
Affiliation(s)
- Sook Won Ryu
- Department of Laboratory Medicine, College of Medicine, Kangwon National University, Chuncheon, Korea
| | | |
Collapse
|
3
|
Seghatchian J. Universal leucodepletion: an overview of some unresolved issues and the highlights of lessons learned. Transfus Apher Sci 2003; 29:105-17. [PMID: 12941346 DOI: 10.1016/s1473-0502(03)00112-5] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Universal leucodepletion (ULD) has been introduced in several countries based on the evidence that selective leucodepletion improves the clinical safety of blood components and based on animal studies that TSE infectivity is 5-7 times higher in the buffy coat than in plasma. Therefore it is perceivable that the removal of the buffy coat, by filtration, removing both leucocytes and platelets, may prove beneficial in reducing the potential risk of transmission of variant CJD by blood components. The implementation of a ULD policy has created some new requirements: Validation/standardisation of various leucodepletion processes to ensure compliance with set specifications. Standardisation/harmonisation of sampling and low leucocyte counting technologies to ensure the interchangeability of results nationally. The establishment of external quality assessment schemes on 'real' leucodepleted products where the cells come in contact with the filter matrix, to monitor the low leucocyte counting performance, nationally. Assessment of filtration-induced generation/retention of major biological response modifiers (BRM), having potential for the development of transfusion reactions. Using these approaches we have identified that, while the overall leucodepletion performance has improved following harmonisation/standardisation of the operational and counting technologies, there are still some unresolved problems and ULD alone may not provide complete protection from some viral transmission such as HTLV and CMV infections or reduction of bacterial sepsis and generation of some BRM. Moreover, ULD has not fully abrogated febrile non-haemolytic transfusion reactions (FNHTR). Therefore the key issue is not the 3-4 log(10) reduction of residual leucocytes but the design of new generation filters or leucodepletion processes with better performance characteristics, to further reduce some specific leucocyte subsets and their fragments as well as reduce the activation of coagulation/complement/kinin and inflammatory systems. Efforts should also be made to reduce the rapid development of apoptotic/necrotic cells and the residual risk associated with plasma, which often contains a vast array of BRM, responsible for residual transfusion reactions. These could only be effectively achieved by working in cooperation with the suppliers of blood component technologies. This overview briefly highlights some of the unresolved issues related to ULD, based on the experience in the UK. Technical details can be found in the reading list provided at the end.
Collapse
Affiliation(s)
- Jerard Seghatchian
- Blood Component Technology and Thrombosis/Haemostasis consultancy, 50 Primrose Hill Road, London NWS 3AA, UK.
| |
Collapse
|
4
|
Gilbert RL, Rider JR, Turton JR, Pamphilon DH. Detection of residual donor leucocytes in leucoreduced red blood cell components using a fluorescence microplate assay. J Immunol Methods 2003; 274:17-25. [PMID: 12609529 DOI: 10.1016/s0022-1759(02)00019-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
In November 1999, universal leucoreduction of blood components was introduced in the UK to minimise the risk of variant Creutzfeldt-Jakob Disease (vCJD) transmission by blood transfusion. The UK specifications for leucodepletion processes state that 99% of leucodepleted components should contain < 5 x 10(6) leucocytes/unit, within 95% confidence limits. However, this leucocyte concentration is below the detection limits of standard haematology analysers. The development of a fluorometric immunoassay to detect the residual donor leucocytes in leucoreduced blood components is described. Monoclonal antibodies to leucocyte-specific cell surface antigens, CD45 and CD15, were adsorbed to the well surface in 96-well microplates. Red blood cell samples containing low numbers of leucocytes were added to the wells and the cells of interest captured by the monoclonal antibodies. Since leucocytes are the only nucleated cells found in significant numbers in blood components they were quantified using PicoGreen, a fluorescent stain specific for dsDNA. In comparison to flow cytometry, the method currently used to detect low numbers of leucocytes, the microplate assay demonstrated excellent sensitivity (1.00) and acceptable specificity (0.81) when standard leucodepleted samples were tested. There was no significant difference between the two methods (p < or = 0.175). In conclusion, the fluorescence microplate assay represents a simple, high throughput alternative to flow cytometry for monitoring leucodepletion compliance in blood banks.
Collapse
Affiliation(s)
- Ruth L Gilbert
- Bristol Institute for Transfusion Sciences, National Blood Service-Bristol Centre, Southmead Road, Bristol BS10 5ND, UK.
| | | | | | | |
Collapse
|
5
|
Cardigan R, Phipps A, Seghatchian J, Bashir S, Aynsley S, Beckman N, Barnett D, Reilly JT, Williamson LM. The development of a national standardized approach for the enumeration of residual leucocytes in blood components. Vox Sang 2002; 83:100-9. [PMID: 12201839 DOI: 10.1046/j.1423-0410.2002.00194.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND AND OBJECTIVES The UK Blood Transfusion Services implemented universal leucocyte depletion of the blood supply in November 1999. To provide statistical process monitoring of these processes, automated methods were introduced to count residual leucocytes (white blood cells) in blood components. MATERIALS AND METHODS Initially in the National Blood Service (NBS) England, protocols were standardized on the use of LeucoCount reagents with either Becton-Dickinson or Beckman Coulter flow cytometers. RESULTS Standardization of protocols resulted in a decreased intersite variability of red cell samples (from 36% to 9% at a level of 11 and 10 cells/ micro l, respectively), and 100% of sites (n = 11) fulfilled the validation criteria. However, we also evaluated the use of alternative reagents with the result that reagents from either Becton-Dickinson or Beckman Coulter, used on either a Becton-Dickinson or Beckman Coulter flow cytometer, passed our validation criteria. CONCLUSIONS It is critical to include samples from filtered products containing white blood cells in validations of leucocyte enumeration methodology, as results may differ between methods using these samples but not using spiked or fixed material. Standardized gating strategies and optimization methods for flow cytometers are critical for obtaining equivalent results with different reagents and instruments.
Collapse
Affiliation(s)
- R Cardigan
- National Blood Service, Brentwood Centre, Crescent Drive, Brentwood, Essex CM15 8DP, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Perrotta PL, Ozcan C, Whitbread JA, Finch SJ. Applying a novel statistical process control model to platelet quality monitoring. Transfusion 2002; 42:1059-66. [PMID: 12385419 DOI: 10.1046/j.1537-2995.2002.00168.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Many countries are implementing universal WBC reduction of blood components Thus, manufacturing procedures must include QC techniques to detect units that fail to meet established standards. STUDY DESIGN AND METHODS A statistical process control model, based on the exponentially weighted moving average of the cumulative distribution function (CDF-EWMA), was developed to detect shifts in a mean and/or variance of a process. The model's parameters (weights) were optimized to maximize detection of an out-of-control process while minimizing sensitivity to autocorrelation. Validation was performed using a retrospective set of WBC-reduction data obtained from a blood bank. The WBC-reduction process was considered in control when there was 95-percent confidence that more than 95 percent of platelet concentrates would contain less than 1 x 10(6) WBCs (6.0 log WBC) as required by European standards. A sentry setting of 5.7 log WBCs was used to allow earlier detection of an out-of-control process. RESULTS Graphic output of the CDF-EWMA model provided a continuous update of the probability that a WBC-reduction process was in control. Using the validation data, the model showed that the process was in control until Observation 332, at which point residual WBCs per unit increased. However, the first platelet concentrate to exceed specified criteria (Observation 346) occurred after the model detected that the process was out of control, demonstrating the forecasting value of this model. This deviation corresponded to an equipment failure in a single apheresis instrument. The Shewhart and EWMA techniques were similarly able to detect when the process was out of control using the test data. CONCLUSION As a statistical process control model, the CDF-EWMA provides real-time estimation of the fraction of components meeting a regulatory limit. It is capable of detecting developing QC problems before units fail to meet regulatory requirements and is a potential alternative to other QC techniques for monitoring WBC reduction of blood components.
Collapse
Affiliation(s)
- P L Perrotta
- Department of Pathology, State University of New York at Stony Brook, USA.
| | | | | | | |
Collapse
|
7
|
Goodfellow KJ, Storie I, Granger V, Whitby L, Antcliffe J, Reilly JT, Barnett D. The United Kingdom National External Quality Assessment Scheme gating and standardization strategy for use in residual WBC counting of WBC-reduced blood components. Transfusion 2002; 42:738-46. [PMID: 12147027 DOI: 10.1046/j.1537-2995.2002.00116.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Major causes of interlaboratory variation in low-level WBC counting are the gating strategies and staining methods employed. To overcome these limitations, a stable low-level WBC control preparation (termed daily run control [DRC]) was developed that when coupled with a new gating strategy will enable international standardization. STUDY DESIGN AND METHODS Both a whole blood preparation (stability of more than 12 months; target WBC count of 20 cells/microL with defined fluorescence values) and a new gating strategy were developed and used with a staining kit (LeucoCOUNT [Becton Dickinson BioSciences] providing the basis for standardization). These were then combined and used to crosscalibrate seven different flow cytometers. After standardization with the DRC, comparative studies were undertaken with fresh samples with a WBC range of <1 to 60 cells per microL. RESULTS The developed gating strategy enabled the DRC WBCs to be positioned to within four channels of the expected target fluorescence 1 value (2.3% variation) and within three channels of the target fluorescence 2 value (0.7% variation) on all evaluated instruments. Subsequent analysis of any sample meant that the WBCs always occupied the same "sample space," irrespective of flow cytometer platform and without the need for repositioning of the analysis region and/or gate. CONCLUSION The cross calibration and standardization of flow cytometers used for low-level WBC counting (irrespective of platform) are attainable with this United Kingdom National External Quality Assessment Scheme strategy. Its adoption should reduce interlaboratory CVs and provide a practical approach for the rapid identification of operator and machine problems.
Collapse
|
8
|
Seghatchian J, Krailadsiri P. Validation of different enrichment strategies for analysis of leucocyte sub-populations: development and application of a new approach, based on leucofiltration. Transfus Apher Sci 2002; 26:61-72. [PMID: 11931379 DOI: 10.1016/s1473-0502(01)00146-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Characterisation of the nature of leucodepletion failure, based on the analysis of leucocyte sub-populations, is an essential task for continual improvement in the clinical safety of blood components and for the selection of a safe and appropriate leucodepletion process. Such information is also critical for improving the quality of filters through an understanding of the mechanism of leucocyte removal filters. Unfortunately, the residual leucocytes of filtered blood components are around the sensitivity of current leucocyte-counting technologies, hence a need for an enrichment process. This preliminary report deals with the merits of various WBC enrichment strategies for the analysis of WBC sub-population subsets. A new procedure, based on refiltering and backflushing the content, with up to 30-fold enrichment, is described. This one-step procedure has the advantage of concentrating both native and atypical leucocytes seen in blood components. The latter may account for lack of interchangeability of results obtained by various counting methods.
Collapse
|
9
|
Seghatchian J, Krailadsiri P, Beard M, Bukasa A, Bashir S. Studies on the characterisation of the cause of leucoreduction failures, with particular reference to extra gatal events. Transfus Apher Sci 2002; 26:47-60. [PMID: 11931378 DOI: 10.1016/s1473-0502(01)00145-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The causes of leucodepletion failure are multifactoral and can be related to haematological variability in blood donors or donation, defective filters, poor specimen handling or ageing, and/or the presence of non-adhering leucocyte/platelets. Since refiltering removes all types of leucocytes, including the populations appearing as extra gated events, we have developed a practical method for refiltering the failed leucodepleted components on standard filters and back-flushing the second filter to assess the nature of the WBC sub-population. In practice, recovered leucocytes from red cell filters and whole blood mainly consist of neutrophils. Those from platelet and plasma filters were mainly lymphocyte with considerable differences depending on the type of leucodepletion process. Atypical leucocytes are often seen in some pre-/post-cellular leucofiltered components. These appear characteristically as small WBC with a lower affinity for filter matrix, or as cell fragment, pinched leucocyte or apoptotic cells. Different reagents in use show variable sensitivity in identifying these extra gatal events. Storage of leucodepleted samples also induces different types of abnormality in leucocyte dot plot. A useful practical approach for characterisation of the nature of leucocyte sub-populations causing failure in leucodepleted components is provided.
Collapse
|
10
|
Seghatchian J, Krailadsiri P, Dilger P, Thorpe R, Wadhwa M. Cytokines as quality indicators of leucoreduced red cell concentrates. Transfus Apher Sci 2002; 26:43-6. [PMID: 11931377 DOI: 10.1016/s1473-0502(01)00144-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Different types of filters are currently used for leucodepletion of red cell concentrates. These filters meet the specification for leucoreduction (<5 x 10(6) leucocytes/ATD) but the quality of the final product may differ depending on the performance of the filters for effective removal of both leucocytes, platelets and possibly cytokines which are associated with transfusion reactions. We measured the levels of three representative cytokines: IL-8, RANTES and TGF-beta1 in red cell concentrates prior to and subsequent to the filtration procedure on day 1 and after a storage period of 35 days. Low levels of IL-8 (10-24 pg/ml) in the control unfiltered concentrates on day 1 which increased by approximately twofold on storage. Filtration reduced the levels of IL-8 on day 1 and day 35, in filtered concentrates in comparison with their control unfiltered counterparts. Leucoreduced concentrates produced by three different filters showed similar IL-8 levels on day 1 and day 35. However, concentrates prepared using another type of process showed a twofold increase in IL-8 levels on storage in comparison with day 1. None of the concentrates tested contained any detectable RANTES and TGF-beta1 suggesting a minimal platelet content. These results indicate that a combination of IL-8, RANTES and TGF-beta1 are useful quality indicators for validation of leucoreduced red cell preparations.
Collapse
Affiliation(s)
- J Seghatchian
- National Blood Service, London and South-East, Colindale, UK.
| | | | | | | | | |
Collapse
|
11
|
Krailadsiri P, Seghatchian J. Residual red cell and platelet content in WBC-reduced plasma measured by a novel flow cytometric method. Transfus Apher Sci 2001; 24:279-86. [PMID: 11791703 DOI: 10.1016/s1473-0502(01)00070-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND The levels of residual red blood cells (RBC) and platelets (PLT) in WBC-reduced plasma are often below the lower detection limit of automated blood cell counters. This study established a novel flow cytometric method for the enumeration of residual RBC and PLT in plasma. Furthermore, their levels in WBC-reduced plasma prepared by using various filters were investigated. MATERIALS AND METHODS WBC-reduced plasma was prepared from two sources: (i) filtration of buffy-coat reduced plasma using dock-on Baxter, Pall and Maco Pharma plasma filters; (ii) filtered whole blood using integral Asahi RZ2000, Maco Pharma LST1, NPBI, and Pall WBF2 whole blood filters. Residual RBC and PLT counts were assessed by using a TruCount tube (Becton Dickinson) containing a known number of lyophilized fluorescent beads. RBC and PLT were labelled with dual monoclonal antibodies, anti-CD41-R-phycoerythrin and anti-glycophorin A-fluorescein isothiocyanide, and analyzed by flow cytometer. RESULTS The flow cytometric method used in this method can detect residual RBC, PLT as well as RBC-MV simultaneously. The sensitivity of the assay was 50 x 10(6) cells/l with the coefficient of variations < or = 10%. Baxter and Maco Pharma plasma filters consistently reduced both RBC, RBC-MV and PLT to below 50 x 10(6/)l. Plasma derived from day 1 RZ2000 filtered whole blood contained PLT below 50 x 10(6) cells/l, whereas day 0 NPBI filtered whole blood showed the highest level of residual PLT. CONCLUSION A sensitive and accurate method for the detection of low levels RBC, RBC-MV, and PLT was established to measure their levels in WBC-reduced plasma. The procedure is simple and practical for routine quality monitoring of plasma, as well as for setting a new specification for WBC-reduced plasma.
Collapse
Affiliation(s)
- P Krailadsiri
- Leucodepletion Proficiency Testing Service, National Blood Service, London, Colindale, UK
| | | |
Collapse
|
12
|
Masse M. Universal leukoreduction of cellular and plasma components: process control and performance of the leukoreduction process. Transfus Clin Biol 2001; 8:297-302. [PMID: 11499981 DOI: 10.1016/s1246-7820(01)00119-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Many countries in Europe and over the world are currently or will be concerned in the near future, by the implementation of universal leukoreduction (ULR) for red blood cells (RBC), platelets (PT) and now also for plasma. Recommended by several advisory committees, this decision to implement ULR must be considered as a recognition of the benefit of early leukocyte removal, and also as a precautionary measure to increase blood safety. The leukodepletion technology for RBC, PT and plasma has become increasingly more elaborated and integrated in the collection or in the component preparation process. To reach this aim and to assure that the end-products meet local specifications (1 or 5 x 10(6) residual leukocytes), a process control and validation program for leukoreduction has been described in the specific guidelines. Tested on a wide scale by a group of centers, flow cytometry is emerging as reference method for residual leukocyte enumeration. Validation protocols (linearity, precision, accuracy) have been defined in numerous national or international studies (PSL and BEST Working Party). The sensitivity of the method is greatly improved by concentration of the sample, with a detection limit equivalent to 10 cells/mL for RBC or PT, and 0.5 cells/mL for plasma. Furthermore, monitoring of the performance of the leukoreduction process includes a quality control program based on a general statistical model with a parametric or non parametric approach, sampling plan, ongoing control, process capability assessment, confidence limit, detection of failure, and estimation of the non conforming units rate.
Collapse
Affiliation(s)
- M Masse
- EFS Bourgogne-Franche-Comté, Besançon, France.
| |
Collapse
|
13
|
Seghatchian J, Krailadsiri P, McCall M. Statistical process monitoring of WBC-reduced blood components assessed by two types of software. Transfusion 2001; 41:102-5. [PMID: 11161253 DOI: 10.1046/j.1537-2995.2001.41010102.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Statistical process control is required for monitoring of the WBC-reduction process. This study focused on some factors that may influence the outcomes of statistical process monitoring, such as WBC-reduction technologies, the anticoagulant used, and WBC-counting technologies, by using two types of software. STUDY DESIGN AND METHODS Data were collected from January to September 1999, before the implementation of universal WBC reduction. The effects of three major factors were investigated: methods of preparation, the addition of EDTA to the sample, and the WBC-counting technologies used (microvolume fluorimetry, flow cytometry, and Nageotte chamber). The WBC-reduction process capability was assessed by two types of software, EZQC (Gambro BCT) and NWA (Northwest Analytical). In addition, the differences between various sets of results were compared by the t test or ANOVA. RESULTS There was no statistical difference (at the 0.05 level of significance) in WBC content when the three types of platelets in citrate samples were compared with EDTA samples. In general, the Nageotte chamber appeared to count the lowest, and microvolume fluorimetry appeared to count lower than flow cytometry. There were minor but significant methodologic differences between the software packages. However, these differences had negligible effects on the percentage of conforming components at both <1 x 10(6) and <5 x 10(6) WBCs per unit. CONCLUSION Only the counting technologies were sufficiently different to warrant consideration. This difference may make unacceptable the interchange of results obtained from various counting methods.
Collapse
Affiliation(s)
- J Seghatchian
- National Leucodepletion Proficiency Service, National Blood Service-London & South East Zone, London, United Kingdom.
| | | | | |
Collapse
|